R
Rezo Therapeutics
Revolutionizing Drug Discovery by Mapping Biological Networks
About Rezo Therapeutics
Rezo Therapeutics, founded in 2021, is a biotechnology firm centered on mapping disease networks to develop precision medicines. The company officially launched in November 2022, securing $78 million in a Series A financing round led by SR One, a16z Bio + Health, and Norwest Venture Partners. This initial funding was aimed at expanding operations and advancing the company's development efforts.
The company's scientific foundation is built upon technology developed at the Quantitative Biosciences Institute (QBI) at the University of California, San Francisco (UCSF). The co-founding team comprises a distinguished group of UCSF scientists and seasoned biotech executives, including Nevan Krogan, Ph.D., Kevan Shokat, Ph.D., Sourav Bandyopadhyay, Ph.D., Natalia Jura, Ph.D., George Scangos, Ph.D., and Norbert Bischofberger, Ph.D. Dr. Krogan, who is also the director of QBI, initially served as the company's CEO and now holds the position of President. His academic work, which combines genetics with molecular and systems biology, is central to Rezo's approach. In August 2025, Derek Hicks, a veteran with over 25 years of experience at firms like Intellia Therapeutics, Spark Therapeutics, and Pfizer, was appointed CEO to guide the company's next growth phase.
Rezo's core is its proprietary "Sequence to Systems to Drugs" (SSD) platform. This platform integrates multiple complex disciplines, including proteomics, genetics, structural biology, chemistry, and bioinformatics, to construct comprehensive maps of molecular disease networks. By analyzing the intricate web of protein-protein, genetic, and biochemical interactions that drive diseases, the SSD platform aims to identify novel, druggable targets that are often missed by traditional, more siloed drug discovery methods. This approach allows for the discovery of tumor-specific vulnerabilities and the development of precision therapies. The business model revolves around leveraging this platform to build a pipeline of therapeutics, initially focusing on solid tumor oncology, with intentions to explore other therapeutic areas through strategic partnerships and collaborations.
Source: Dealroom company dataNews
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Nov 2022 | $78M | $312M | SV Angel · Hawktail · Andreessen Horowitz · Norwest Venture Partners | ↗ |
| SPINOUTOther financing | Jan 2021 | $0 | — | University of California, San Francisco | — |
Growth signals
Latest recorded traffic for Rezo Therapeutics is 5.5K monthly website visits, up 139.1% over the last three months. Rezo Therapeutics's team grew 15.8% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Rezo Therapeutics in the San Francisco ecosystem
The Rezo Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Andreessen Horowitz
Norwest Venture PartnersSR One
SV Angel
Hawktail
Liquid 2 Ventures
Other known investors1 additional known investor
University of California, San Francisco
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Rezo Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Rezo Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








